|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, our findings also suggest that reduction of COX-2 using nonsteroidal anti-inflammatory drugs in gastric cancer chemoprevention may only be relevant for older patients.
|
19940363 |
2009 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that induction of 15-LOX-1-mediated down-regulation of a PPAR-gamma and COX-2 pathway by honokiol may be a promising therapeutic strategy for gastric cancer.
|
20649594 |
2010 |
|
Malignant neoplasm of stomach
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The -765C, -1195A, -1290G, *2430T alleles and *429TT genotype of COX-2 polymorphisms were determined a significant association with susceptibility to GC.
|
21086572 |
2010 |
|
Malignant neoplasm of stomach
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggested that the COX-2 promoter polymorphisms were associated with increased risk of GC, especially interacting with H. pylori infection.
|
21538574 |
2011 |
|
Malignant neoplasm of stomach
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
COX-2 -899C carrier genotype and Helicobacter pylori positive infection may have a synergistic effect on gastric cancer in high incidence Hexi area of Gansu Province in China.
|
20364406 |
2011 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
COX-2 might mediate tumor angiogenesis and growth, and could be considered as a target for gastric cancer therapy.
|
21266034 |
2011 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Notch2-induced COX-2 expression enhancing gastric cancer progression.
|
21976141 |
2012 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
COX-2 is overexpressed in various cancers, including gastric cancer.
|
22385256 |
2012 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
COX-2 regulates E-cadherin expression through the NF-κB/Snail signaling pathway in gastric cancer.
|
23670240 |
2013 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mechanism as to how COX2 is regulated during the gastric cancer development is largely unknown.
|
24308961 |
2014 |
|
Malignant neoplasm of stomach
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Therefore, our results suggest that the methylation status of the gene COX2 is associated with the intestinal type of gastric cancer.
|
24014049 |
2014 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these findings provide new evidence for a positive feedback loop between STAT3 signaling and COX-2 in H. pylori pathogenesis and may lead to new approaches for early detection and effective therapy of gastric cancer
|
24127267 |
2014 |
|
Malignant neoplasm of stomach
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among the Chinese Hui ethnic group COX-2 -765 C allele carriers were at increased risk for gastric cancer (OR=1.977, 95%CI=1.104-3.541).
|
24935598 |
2014 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We confirm loss of ANXA1 and overexpression of COX-2 in clinical gastric cancer, suggesting that the anti-proliferative function of ANXA1 against COX-2 production might be lost.
|
25038797 |
2014 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of anti-LeY antibody in the downregulation of MAPKs/COX-2 pathway in gastric cancer.
|
24533777 |
2014 |
|
Malignant neoplasm of stomach
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we examined two single nucleotide polymorphism (SNP) sites of COX-2 gene in gastric cancer patients and explored the effect of the SNPs on the morbidity of gastric cancer.
|
27352184 |
2015 |
|
Malignant neoplasm of stomach
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
No significant association was found between COX-2 methylation and risk of GC (OR, 1.15; 95% CI: 0.70-1.88).
|
26674784 |
2015 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways.
|
27079437 |
2016 |
|
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the overexpression of transcription factor C/EBPβ in gastric cancer interacted with NFκB and further regulates COX-2 expression.
|
26514342 |
2016 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Curcumin Enhances the Anticancer Effect Of 5-fluorouracil against Gastric Cancer through Down-Regulation of COX-2 and NF- κB Signaling Pathways.
|
29151957 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
In 180 cases of GC, the clinicopathologic features were correlated with the results obtained after paired immunohistochemical stains (tumor/normal mucosa) with 15 antibodies: E-cadherin, HER-2, VEGF, CD31, CD105, COX-2, maspin, bax, bcl-2, p53, Ki67, MLH-1, MSH-2, Mena protein, and vimentin.
|
26067133 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compound Wumei Powder Inhibits the Invasion and Metastasis of Gastric Cancer via Cox-2/PGE2-PI3K/AKT/GSK3<i>β</i>/<i>β</i>-Catenin Signaling Pathway.
|
29358963 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined administration of γ-secretase and COX-2 inhibitor produced a marked inhibition of growth in AGS cells, which suggests that patients with poorly differentiated GC may benefit from the blockage of NICD, which potentially serves a role in GC differentiation.
|
29616098 |
2018 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
COX-2 and MMP-13 can be used as reference indexes to guide the treatment of gastric cancer and predict the disease prognosis.
|
30941969 |
2019 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
COX2 -1195G > A polymorphism may serve as a genetic biomarker of gastric cancer in both Asians and Caucasians.
|
30391440 |
2019 |